Clinical Trial Update: Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating aflibercept in neovascular age-related macular degeneration patients who are non-responders to anti-VEGF therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Barcelona Macula Foundation | Conditions: Wet Macular Degeneration | Phase 4 | Status: COMPLETED